Trial Profile
A multicenter retrospective study assessing ipilimumab or the combination of ipilimumab plus nivolumab after anti-PD-1 treatment failure, in advanced melanoma patients
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Feb 2017 New trial record
- 16 Feb 2017 Results published in the European Journal of Cancer